@article{10902/30697,
year = {2023},
url = {https://hdl.handle.net/10902/30697},
abstract = {Objective
The current analysis of the MAXIMISE trial was conducted to investigate the presence of post-inflammatory and degenerative spinal changes and inflammatory changes in spinal processes identified in baseline MRIs and their potential for predicting differential treatment effects in a cohort of PsA patients with axial manifestations.

Methods
Baseline spinal MRIs from the MAXIMISE trial were re-read to identify additional inflammatory (spinal process), post-inflammatory, and degenerative changes, and investigate the differential treatment effect of these imaging features using logistic regression modelling.

Results
In addition to bone marrow oedema assessed at primary analysis, spinal process inflammation and post-inflammatory changes evaluated by FAt Spondyloarthritis Spine Score were documented in 11.1% and 20.2% patients, respectively. At least one type of degenerative change was noted in 64% patients, with Pfirrmann grade ≥3 (51.1%) being the most common. Combining primary and re-read MRI findings, 67.1% of patients presented with inflammatory or post-inflammatory changes while 21.2% had degenerative changes alone. Although not statistically significant, post-inflammatory changes were associated with a trend for better efficacy outcomes in terms of ASAS20, ASAS40 and BASDAI50 responses; a trend for worse outcomes was observed in the presence of degenerative changes.

Conclusion
The current analysis revealed the occurrence of additional inflammatory and post-inflammatory changes suggestive of axial PsA (axPsA) and a trend for better clinical outcomes for patients treated with secukinumab. These results elucidate the imaging characteristics and improve our current understanding of axPsA thereby supporting the interpretation of future trials.},
organization = {Funding. This study was supported by Novartis Pharma AG, Switzerland.
Disclosure statement: X.B.: consultancy honoraria and research grants: AbbVie, BMS, Galapagos, Chugai, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz and UCB; E.P.: employee
of Novartis with Novartis stock; L.C.: grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Pfizer and Novartis; consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer and UCB; and speaker for AbbVie, Amgen, Biogen, Celgene, Gilead, Eli Lilly, Janssen, Medac, Novartis, Pfizer and UCB; R.B.: research grants: AbbVie, MSD and Roche; consulting fees: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCB pharma and MSD; speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCB pharma, MSD and Lilly; V.N.C.: research grants/honoraria
from AbbVie, Galapagos, Janssen, Lilly, Moonlake, Novartis, Pfizer and UCB; E.O.: employee of Novartis; B.S.: was an employee of Novartis until manuscript submission and currently working as an employee of GKM Gesellschaft fuer Therapieforschung mbH; R.L.: research grants: AbbVie, Novartis, Pfizer and UCB; speakers bureau: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Eli-Lilly, Janssen, Gilead, Galapagos, Glaxo-Smith-Kline, Novartis, Pfizer and UCB.
Patient consent for publication: Not required.
Acknowledgements. The authors thank the patients and the study investigators who participated in this study. The authors also thank Andrew Franklin (Novartis Pharma AG, Basel, Switzerland) for the valuable review. Medical writing support, under the
guidance of the authors, was provided by Dhanya Mukundan and Rajeeb Ghosh, Novartis Healthcare Private Limited, Hyderabad, India.},
publisher = {Oxford University Press},
publisher = {Rheumatology, 2023, 00, 1-8},
title = {Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort},
author = {Baraliakos, Xenofon and Pournara, Effie and Coates, Laura C. and Navarro-Compán, Victoria and Blanco Alonso, Ricardo and O'Brien, Eamonn and Schulz, Barbara and Landewe, Robert},
}